BUZZ-Celcuity 因 H.C. Wainwright 将其评级下调至 "中性 "而下跌

路透中文
Nov 18
BUZZ-Celcuity 因 H.C. Wainwright 将其评级下调至 "中性 "而下跌

11月17日 - ** H.C. Wainwright将癌症诊断公司Celcuity CELC.O的评级从 "买入 "下调至 "中性";将目标价从77美元上调至94美元

** 券商认为,这家尚未实现盈利的公司只有gedatolisib一项资产,估值43亿美元,是一只定价完美的股票,下跌风险大于上涨风险。

** CELC 的股价今年以来已上涨约 608

** H.C.Wainwright指出,FDA已经接受了gedatolisib治疗野生型PIK3CA乳腺癌的NDA,但潜在的延迟、大型制药公司的激烈竞争以及定价或采用率低于预期等风险依然存在。

** Celcuity CELC.O (link) 股价在下午交易中下跌约 2.96%,至 89.94 美元。

** 九家券商中有八家将其股票评级为 "买入 "或更高,一家为 "持有";PT 中值为 96.50 美元--数据由 LSEG 编制

** 包括本交易日的走势在内,CELC 的股价在今年累计上涨了约 587.1

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10